Voyager Therapeutics to present VY1706 Alzheimer's gene therapy study design at CTAD 2026

VYGR•2026-10-27

Voyager Therapeutics will present Alzheimer's study posters Nov. 16-17 at CTAD 2026 in Boston. One will outline a first-in-human study of VY1706, a gene therapy designed to lower tau production in early Alzheimer's disease.

1. Poster presentations

Voyager Therapeutics will present Alzheimer's study posters Nov. 16-17 at CTAD 2026, which runs Nov. 16-19 in Boston. The VY1706 poster will outline a first-in-human study of the gene therapy designed to lower tau production in early Alzheimer's disease.

2. Antibody study

A second poster will describe baseline participant characteristics in a multiple ascending dose study of VY7523, an anti-tau antibody in early Alzheimer's disease.

Voyager Therapeutics to present VY1706 Alzheimer's gene therapy study design at CTAD 2026

1. Poster presentations

2. Antibody study

Related News

First Watch extends partnership with NCR Voyix to implement Aloha Next across nearly 600 restaurants

Xtend secures $2.35 million Middle East defense order one day after reporting nine-month revenue above full-year 2025

Vanda Pharmaceuticals target price cut to $4.50 from $5.75

CF Industries Holdings Inc: UBS raises target price to $134 from $123

US September durable goods orders data